Protective effects of fluoxetine on decompression sickness in mice.

Massive bubble formation after diving can lead to decompression sickness (DCS) that can result in central nervous system disorders or even death. Bubbles alter the vascular endothelium and activate blood cells and inflammatory pathways, leading to a systemic pathophysiological process that promotes...

Full description

Bibliographic Details
Main Authors: Jean-Eric Blatteau, Sandrine Barre, Aurelie Pascual, Olivier Castagna, Jacques H Abraini, Jean-Jacques Risso, Nicolas Vallee
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3493517?pdf=render
id doaj-0b112323c49e4c2ea4ec1480c4da40b9
record_format Article
spelling doaj-0b112323c49e4c2ea4ec1480c4da40b92020-11-25T01:37:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01711e4906910.1371/journal.pone.0049069Protective effects of fluoxetine on decompression sickness in mice.Jean-Eric BlatteauSandrine BarreAurelie PascualOlivier CastagnaJacques H AbrainiJean-Jacques RissoNicolas ValleeMassive bubble formation after diving can lead to decompression sickness (DCS) that can result in central nervous system disorders or even death. Bubbles alter the vascular endothelium and activate blood cells and inflammatory pathways, leading to a systemic pathophysiological process that promotes ischemic damage. Fluoxetine, a well-known antidepressant, is recognized as having anti-inflammatory properties at the systemic level, as well as in the setting of cerebral ischemia. We report a beneficial clinical effect associated with fluoxetine in experimental DCS. 91 mice were subjected to a simulated dive at 90 msw for 45 min before rapid decompression. The experimental group received 50 mg/kg of fluoxetine 18 hours before hyperbaric exposure (n = 46) while controls were not treated (n = 45). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and cytokine IL-6 detection. There were significantly fewer manifestations of DCS in the fluoxetine group than in the controls (43.5% versus 75.5%, respectively; p = 0.004). Survivors showed a better and significant neurological recovery with fluoxetine. Platelets and red cells were significantly decreased after decompression in controls but not in the treated mice. Fluoxetine reduced circulating IL-6, a relevant marker of systemic inflammation in DCS. We concluded that fluoxetine decreased the incidence of DCS and improved motor recovery, by limiting inflammation processes.http://europepmc.org/articles/PMC3493517?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jean-Eric Blatteau
Sandrine Barre
Aurelie Pascual
Olivier Castagna
Jacques H Abraini
Jean-Jacques Risso
Nicolas Vallee
spellingShingle Jean-Eric Blatteau
Sandrine Barre
Aurelie Pascual
Olivier Castagna
Jacques H Abraini
Jean-Jacques Risso
Nicolas Vallee
Protective effects of fluoxetine on decompression sickness in mice.
PLoS ONE
author_facet Jean-Eric Blatteau
Sandrine Barre
Aurelie Pascual
Olivier Castagna
Jacques H Abraini
Jean-Jacques Risso
Nicolas Vallee
author_sort Jean-Eric Blatteau
title Protective effects of fluoxetine on decompression sickness in mice.
title_short Protective effects of fluoxetine on decompression sickness in mice.
title_full Protective effects of fluoxetine on decompression sickness in mice.
title_fullStr Protective effects of fluoxetine on decompression sickness in mice.
title_full_unstemmed Protective effects of fluoxetine on decompression sickness in mice.
title_sort protective effects of fluoxetine on decompression sickness in mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Massive bubble formation after diving can lead to decompression sickness (DCS) that can result in central nervous system disorders or even death. Bubbles alter the vascular endothelium and activate blood cells and inflammatory pathways, leading to a systemic pathophysiological process that promotes ischemic damage. Fluoxetine, a well-known antidepressant, is recognized as having anti-inflammatory properties at the systemic level, as well as in the setting of cerebral ischemia. We report a beneficial clinical effect associated with fluoxetine in experimental DCS. 91 mice were subjected to a simulated dive at 90 msw for 45 min before rapid decompression. The experimental group received 50 mg/kg of fluoxetine 18 hours before hyperbaric exposure (n = 46) while controls were not treated (n = 45). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and cytokine IL-6 detection. There were significantly fewer manifestations of DCS in the fluoxetine group than in the controls (43.5% versus 75.5%, respectively; p = 0.004). Survivors showed a better and significant neurological recovery with fluoxetine. Platelets and red cells were significantly decreased after decompression in controls but not in the treated mice. Fluoxetine reduced circulating IL-6, a relevant marker of systemic inflammation in DCS. We concluded that fluoxetine decreased the incidence of DCS and improved motor recovery, by limiting inflammation processes.
url http://europepmc.org/articles/PMC3493517?pdf=render
work_keys_str_mv AT jeanericblatteau protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT sandrinebarre protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT aureliepascual protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT oliviercastagna protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT jacqueshabraini protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT jeanjacquesrisso protectiveeffectsoffluoxetineondecompressionsicknessinmice
AT nicolasvallee protectiveeffectsoffluoxetineondecompressionsicknessinmice
_version_ 1725058338989801472